Marathon Pharmaceuticals Charging $89,000 for Muscular Dystrophy Drug
February 13, 2017
2,466
19
4
0.93%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
The Wall Street Journal Episodes Around February 13, 2017
See what was published immediately before and after this episode.
4:55Now PlayingMarathon Pharmaceuticals Charging $89,000 for Muscular Dystrophy Drug
YouTube Description
as posted by the channelMarathon Pharmaceuticals plans to sell a the drug deflazacort, used to treat a rare form of muscular dystrophy for $89,000 annually in the U.S., roughly 70 times the cost of the drug overseas. WSJ's Joseph Walker and Tanya Rivero discuss the move. Photo: Zuma Press
Subscribe to the WSJ channel here:
More from the Wall Street Journal:
Visit WSJ.com
Follow WSJ on Facebook
Follow WSJ on Google+
Follow WSJ on Twitter
Follow WSJ on Instagram
Follow WSJ on Pinterest
Don’t miss a WSJ video, subscribe here
More from the Wall Street Journal:
Visit WSJ.com
Visit the WSJ Video Center
On Facebook
On Snapchat
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.